Table 5.

Published details of other double ALK fusion positive NSCLC patients treated with ALK-TKIs.

	Ref	Year	Double Fusion	ALK-TKIs	Treatment	Response
1	Wu, X. et al. [104]	2020	CCNY-ALK ATIC-ALK	Crizotinib	First line	PR > 6 m
2	Wu, X. et al. [105]	2020	NLRC4-ALK;EML4-ALK	Crizotinib	First line	PFS > 10 m
3	Luo, J. et al. [106]	2019	PRKCB-ALK; EML4-ALK	Crizotinib Ceritinib	First line Second line	PFS: 6 m PFS > 2 m
4	Qin, B. et al. [107]	2019	BCL11A-ALK; EML4-ALK	Crizotinib	First line	PFS: 13 m
5	Lin, H. et al. [108]	2018	FBXO11-ALK; EML6-ALK	Crizotinib	Second line	PFS > 11 m
6	Yin, J. et al. [109]	2018	DYSF-ALK; ITGAV-ALK	Crizotinib	Second line	PFS > 3 m
7	Tao, H. et al. [110]	2022	ALK-SSH2; EML4-ALK	Crizotinib	First line	PFS: 9 m
8	Tao, H. et al. [110]	2022	ARID2-ALK; EML4-ALK	Crizotinib	First line	PFS: 12 m
9	Guo, J. et al. [111]	2020	CDK15-ALK; EML4-ALK	Crizotinib	Second line	PFS: 23 m
10	Zeng, H. et al. [68]	2021	PDK1-ALK; STRN-ALK	Alectinib	First line	PFS > 11 m
11	Zhai, X. et al. [112]	2022	ALK-GCA; EML4-ALK	Alectinib	First line	PFS > 20 m